Was just rolling some things over in my mind and the thought of what might be the best possible outcome led me to this scenario.  Its predicated on the assumption that Apabetlone will be an approved drug sometime within the next 12 to 18 months or so...give or take.  That might not happen of course, but this is a "best case" not worst case scenario.

Perhaps a deal with Sanofi or some other company for licensing of Apabetalone in the Eurozone...

Esperion just got $300 million for their cholesterol lowering drug in Europe, $150 million up front with the remainging $150 to be paid after first sales.  After that there could be milestone payments that might be worth up to $600 million.  

https://www.biopharmadive.com/news/esperion-bempedoic-acid-daiichi-license-cholesterol/545236/

That's for a drug that's completed phase III trials of course...we're not there yet.  But any deal that would provide enough funds to continue without all these piddly raises that only are good for one or just a few months.